查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
歐洲癲癇市場預測至 2030 年 - 區域分析 - 按類型、給藥途徑、治療類型、年齡層和配銷通路
市場調查報告書
商品編碼
1592590

歐洲癲癇市場預測至 2030 年 - 區域分析 - 按類型、給藥途徑、治療類型、年齡層和配銷通路

Europe Epilepsy Market Forecast to 2030 - Regional Analysis - by Type, Route of Administration, Treatment Type, Age Group, and Distribution Channel
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 訂單完成後即時交付

價格

2022年歐洲癲癇市場價值為19.4058億美元，預計到2030年將達到26.2605億美元；預計2022年至2030年複合年成長率為3.9%。

增加對癲癇療法開發的投資推動歐洲癲癇市場

隨著技術的快速發展和創新，醫療保健產業正在發生變革，提高了醫療保健服務和照護品質。癲癇市場的特徵是存在多家小型和大型公司和組織，實施各種成長策略。資金的可用性使公司和組織能夠提高生產水平，拓展新市場，投資新的/改進的技術，並為研發分配更多資源。以下提到了癲癇市場上一些對市場進步有貢獻的著名投資。

2023 年 3 月，瑞典政府決定委託瑞典創新機構 Vinnova 撥款 770 萬美元（8,000 萬瑞典克朗）建立國家創新集群，用於細胞療法和藥物的商業化、技能開發和生產能力建設。 ，例如基因療法。

2022 年 11 月，英國阿斯頓大學的科學家致力於開發預防兒童癲癇發作的新藥物治療項目，獲得了 240 萬美元（200 萬英鎊）的資助，以發現大腦中的疾病機制和預防癲癇的方法。這個為期三年的計畫由醫學研究委員會資助，由阿斯頓大學健康與生命科學學院的研究人員與布里斯託大學和 Jazz Pharmaceuticals 共同領導。

2022 年 7 月，Cerebral Therapeutics 在 C 輪融資中獲得了 4,000 萬美元，為其植入式輸注癲癇治療做好第三階段開發的準備。此輪融資由 Lynx1 Capital Management 領投，其他投資者包括 RA Capital Management 和 Perceptive Advisors。 Cerebral Therapeutics 旨在將指定水平的丙戊酸輸送至中樞神經系統，而不引起體重增加，這一點在口服製劑研究的受試者中得到了證實。

2021 年 11 月，位於印第安納州的新創公司 Neurava 獲得了超過 65 萬美元的種子資金，由 Elevate Ventures 領投，普渡大學 Foundry、UCB Biopharma、First Leaf Capital、iO Life Ventures 和天使投資者跟隨。該公司正在開發一款穿戴式設備，用於監測和提醒用戶癲癇引起的猝死風險即將來臨。

2021 年 6 月，生物治療公司 Neurona Therapeutics Inc. 成功完成了 4,150 萬美元融資，以推進該公司針對各種適應症的全資現成細胞療法產品線，包括 NRTX-1001（1 期/ 2a 臨床研究） ，一種用於治療慢性局部癲癇的抑制性神經元細胞療法。

因此，增加對先進治療方法開發的投資推動了癲癇市場的成長。

歐洲癲癇市場概況

歐洲癲癇市場分為德國、英國、法國、義大利、西班牙和歐洲其他地區。該地區在癲癇市場佔有重要的市場佔有率。由於老年人口顯著成長、監管機構批准新藥、政府增加資金以改善和開發有效的癲癇藥物和治療方法等因素，預計歐洲癲癇市場在預測期內將出現顯著成長。

歐洲癲癇市場收入及 2030 年預測（百萬美元）

歐洲癲癇市場細分

歐洲癲癇市場按類型、給藥途徑、治療類型、年齡層、配銷通路和國家分類。

依類型，歐洲癲癇市場分為進行性肌陣攣癲癇、反射性癲癇、全身性癲癇等。 2022 年，全身性癲癇細分市場佔最大市場。

就給藥途徑而言，歐洲癲癇市場分為口服、腸胃外和其他。 2022 年，口腔細分市場佔據最大的市場佔有率。

依治療類型，歐洲癲癇市場分為第一代藥物、第二代藥物和第三代藥物。 2022年，第三代藥物細分市場佔據最大市場佔有率。

根據年齡層，歐洲癲癇市場分為成人和兒童。 2022 年，成人細分市場將佔據更大的市場佔有率。

從配銷通路來看，歐洲癲癇市場分為醫院藥局、零售藥局等。 2022年，醫院藥局領域佔據最大的市場佔有率。

依國家分類，歐洲癲癇市場分為英國、德國、法國、義大利、西班牙和歐洲其他地區。 2022 年，英國在歐洲癲癇市場佔有率中佔據主導地位。

Abbott Laboratories、Pfizer Inc、Eisai Co Ltd、UCB SA、CombiGene AB、LivaNova Plc、Novartis AG、Medtronic Plc、GSK Plc 和 H. Lundbeck AS 是歐洲癲癇市場上的一些領先公司。

目錄

第 1 章：簡介

第 2 章：執行摘要

  • 主要見解
  • 市場吸引力

第 3 章：研究方法

  • 覆蓋範圍
  • 二次研究
  • 初步研究

第 4 章：歐洲癲癇治療方法的管道研究

  • 癲癇治療方法的管道研究
    • 細胞和基因治療方法
    • 膠囊細胞生物遞送（ECB）系統
    • 癲癇基因治療臨床概述
      • 癲癇臨床研究採用基因療法
      • 癲癇病毒載體的管道研究
      • 癲癇非病毒載體的管道研究
      • 腺相關病毒 (AAV) 介導的神經調節胜肽 - 概述
      • 基因治療方法的神經營養因子
      • 人類癲癇表現型的鉀通道
      • 酶誘導抗癲癇藥

第 5 章：歐洲癲癇市場 - 主要市場動態

  • 市場促進因素
    • 癲癇盛行率上升
    • 增加癲癇療法開發的投資
  • 市場限制
    • 產品召回
  • 市場機會
    • 組織所進行的意識計畫激增
  • 未來趨勢
    • 基因療法作為有前景的治療方法
  • 促進因素和限制的影響：

第 6 章：癲癇市場 - 歐洲分析

  • 歐洲：癲癇市場

第 7 章：歐洲癲癇市場分析 - 按類型

  • 概述
  • 進行性肌陣攣癲癇
  • 反射性癲癇
  • 全身性癲癇
  • 其他

第 8 章：歐洲癲癇市場分析 - 按給藥途徑

  • 概述
  • 口服
  • 注射用
  • 其他

第 9 章：歐洲癲癇市場分析 - 按治療類型

  • 概述
  • 第一代藥物
  • 第二代藥物
  • 第三代藥物

第 10 章：歐洲癲癇市場分析 - 按年齡層

  • 概述
  • 成人
  • 孩子們

第 11 章：歐洲癲癇市場分析 - 按配銷通路

  • 概述
  • 醫院藥房
  • 零售藥局
  • 其他

第 12 章：歐洲癲癇市場 - 國家分析

  • 歐洲
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區

第 13 章：產業格局

  • 概述
  • 癲癇市場的成長策略
  • 有機成長策略
    • 概述
  • 無機成長策略
    • 概述

第 14 章：公司簡介

  • Abbott Laboratories
  • Pfizer Inc
  • Eisai Co Ltd
  • UCB SA
  • CombiGene AB
  • LivaNova Plc
  • Novartis AG
  • Medtronic Plc
  • GSK Plc
  • H. Lundbeck AS

第 15 章：附錄

Product Code: BMIRE00030744

The Europe epilepsy market was valued at US$ 1,940.58 million in 2022 and is expected to reach US$ 2,626.05 million by 2030; it is estimated to register a CAGR of 3.9% from 2022 to 2030.

Increasing Investments in Development of Epilepsy Therapies Drive Europe Epilepsy Market

The healthcare sector is transforming with rapid technological developments and innovation, enhancing healthcare services and quality of care. The epilepsy market is characterized by the presence of several small and large companies and organizations implementing various growth strategies. The availability of funding enables companies and organizations to boost production levels, expand into new markets, invest in new/improved technologies, and allocate more resources to R&D. A few of the notable investments in the epilepsy market, contributing to the market progress, have been mentioned below.

In March 2023, the Swedish government decided to commission Vinnova, Sweden's innovation agency, a total of US$ 7.7 million (80 million SEK) to establish a national innovation cluster for commercialization, skills development, and production capacity build-up for cell therapies and other advanced treatments such as gene therapy.

In November 2022, Scientists at Aston University in the UK, working on a project to develop new drug treatments to prevent the beginning of childhood epilepsy, were awarded US$ 2.4 million (£2 million) to discover the disease mechanism in the brain and the ways of epilepsy prevention. This three-year project funded by the Medical Research Council is a collaboration led by researchers in the College of Health and Life Sciences at Aston University, combined with Bristol University and Jazz Pharmaceuticals.

In July 2022, Cerebral Therapeutics secured US$ 40 million in the Series C round funding to get its implanted infusion epilepsy treatment ready for phase 3 development. The funding round was led by Lynx1 Capital Management among other investors, including RA Capital Management and Perceptive Advisors. Cerebral Therapeutics intends to deliver the specified levels of valproate to the central nervous system without causing weight gain, which was witnessed in subjects of oral formulation studies.

In November 2021, Neurava, a startup located in Indiana, received over US$ 0.65 million in seed funding led by Elevate Ventures with participation from Purdue Foundry, UCB Biopharma, First Leaf Capital, iO Life Ventures, and angel investors. The company is working on the development of a wearable device to monitor and alert users about the approaching risk of sudden, unexpected death caused by epilepsy.

In June 2021, Neurona Therapeutics Inc., a biotherapeutics company, successfully completed a US$ 41.5 million financing to advance the company's pipeline of wholly owned, off-the-shelf cell therapies for various indications, including NRTX-1001 (a Phase 1/2a clinical study), an inhibitory neuronal cell therapy for the treatment of chronic focal epilepsy.

Therefore, increasing investments in the development of advanced treatments propels the growth of the epilepsy market.

Europe Epilepsy Market Overview

The European epilepsy market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The region holds a significant market share in the epilepsy market. The European epilepsy market is expected to witness significant growth during the forecast period due to factors such as the significant growth in elderly population, approvals of new drugs by regulatory authorities, increase in funding by governments to improve and develop effective drugs and treatments for seizures in the region.

Europe Epilepsy Market Revenue and Forecast to 2030 (US$ Million)

Europe Epilepsy Market Segmentation

The Europe epilepsy market is categorized into type, route of administration, treatment type, age group, distribution channel, and country.

Based on type, the Europe epilepsy market is categorized into progressive myoclonic epilepsy, reflex epilepsy, generalized epilepsy, and other. The generalized epilepsy segment held the largest market share in 2022.

In terms of route of administration, the Europe epilepsy market is categorized into oral, parenteral, and others. The oral segment held the largest market share in 2022.

By treatment type, the Europe epilepsy market is segmented into first generation drugs, second generation drugs, and third generation drugs. The third generation drugs segment held the largest market share in 2022.

Based on age group, the Europe epilepsy market is bifurcated into adult and children. The adult segment held a larger market share in 2022.

In terms of distribution channel, the Europe epilepsy market is categorized into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held the largest market share in 2022.

By country, the Europe epilepsy market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. The UK dominated the Europe epilepsy market share in 2022.

Abbott Laboratories, Pfizer Inc, Eisai Co Ltd, UCB SA, CombiGene AB, LivaNova Plc, Novartis AG, Medtronic Plc, GSK Plc, and H. Lundbeck AS are some of the leading companies operating in the Europe epilepsy market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Europe Pipeline Studies for Epilepsy Therapy Approaches

  • 4.1 Pipeline Studies for Epilepsy Therapy Approaches
    • 4.1.1 Cell and Gene Therapy Approaches
    • 4.1.2 Encapsulated cell bio delivery (ECB) system
    • 4.1.3 Gene Therapy for Epilepsy Clinical Overview
      • 4.1.3.1 Genetic Therapies Adopted for Clinic Research of Epilepsy
        • 4.1.3.1.1 Gene Supplementation - Overview
        • 4.1.3.1.2 Gene Modulation - Overview
        • 4.1.3.1.3 Antisense Oligonucleotides and RNA Interference - Overview
        • 4.1.3.1.4 Neuropeptides - Overview
        • 4.1.3.1.5 Engineered Channels - Overview
        • 4.1.3.1.6 Endogenous Channels - Overview
      • 4.1.3.2 Pipeline Studies of Viral Vectors for Epilepsy
      • 4.1.3.3 Pipeline Studies of Non-Viral Vectors for Epilepsy
        • 4.1.3.3.1 Polymer-based Non-Viral Vectors for Epilepsy
        • 4.1.3.3.2 Lipid-based Non-Viral Vectors for Epilepsy
      • 4.1.3.4 Adeno-Associated Virus (AAV)-Mediated Neuromodulatory Peptides - Overview
      • 4.1.3.5 Neurotrophic Factors for Gene Therapy Approaches
      • 4.1.3.6 Potassium Channels For Human Epileptic Phenotypes
      • 4.1.3.7 Enzyme Inducing Antiepileptic Drugs

5. Europe Epilepsy Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Rising Prevalence of Epilepsy
    • 5.1.2 Increasing Investments in Development of Epilepsy Therapies
  • 5.2 Market Restraints
    • 5.2.1 Recall of Products
  • 5.3 Market Opportunities
    • 5.3.1 Surge in Awareness Programs Conducted by Organizations
  • 5.4 Future Trends
    • 5.4.1 Gene Therapy as Promising Treatment Approach
  • 5.5 Impact of Drivers and Restraints:

6. Epilepsy Market - Europe Analysis

  • 6.1 Europe: Epilepsy Market

7. Europe Epilepsy Market Analysis - by Type

  • 7.1 Overview
  • 7.2 Progressive Myoclonic Epilepsy
    • 7.2.1 Overview
    • 7.2.2 Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.3 Reflex Epilepsy
    • 7.3.1 Overview
    • 7.3.2 Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Generalized Epilepsy
    • 7.4.1 Overview
    • 7.4.2 Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 Other
    • 7.5.1 Overview
    • 7.5.2 Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Epilepsy Market Analysis - by Route of Administration

  • 8.1 Overview
  • 8.2 Oral
    • 8.2.1 Overview
    • 8.2.2 Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.3 Parenteral
    • 8.3.1 Overview
    • 8.3.2 Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Others
    • 8.4.1 Overview
    • 8.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

9. Europe Epilepsy Market Analysis - by Treatment Type

  • 9.1 Overview
  • 9.2 First Generation Drugs
    • 9.2.1 Overview
    • 9.2.2 First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.3 Second Generation Drugs
    • 9.3.1 Overview
    • 9.3.2 Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.4 Third Generation Drugs
    • 9.4.1 Overview
    • 9.4.2 Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

10. Europe Epilepsy Market Analysis - by Age Group

  • 10.1 Overview
  • 10.2 Adult
    • 10.2.1 Overview
    • 10.2.2 Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.3 Children
    • 10.3.1 Overview
    • 10.3.2 Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

11. Europe Epilepsy Market Analysis - by Distribution Channel

  • 11.1 Overview
  • 11.2 Hospital Pharmacies
    • 11.2.1 Overview
    • 11.2.2 Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 11.3 Retail Pharmacies
    • 11.3.1 Overview
    • 11.3.2 Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 11.4 Others
    • 11.4.1 Overview
    • 11.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

12. Europe Epilepsy Market - Country Analysis

  • 12.1 Europe: Epilepsy Market Overview
    • 12.1.1 Europe: Epilepsy Market Breakdown, by Key Country, 2022 and 2030 (%)
      • 12.1.1.1 United Kingdom: Epilepsy Market Overview
      • 12.1.1.2 United Kingdom: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
        • 12.1.1.2.1 United Kingdom: Epilepsy Market Breakdown, by Type
        • 12.1.1.2.2 United Kingdom: Epilepsy Market Breakdown, by Route of Administration
        • 12.1.1.2.3 United Kingdom: Epilepsy Market Breakdown, by Treatment Type
        • 12.1.1.2.4 United Kingdom: Epilepsy Market Breakdown, by Age Group
        • 12.1.1.2.5 United Kingdom: Epilepsy Market Breakdown, by Distribution Channel
      • 12.1.1.3 Germany: Epilepsy Market Overview
      • 12.1.1.4 Germany: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
        • 12.1.1.4.1 Germany: Epilepsy Market Breakdown, by Type
        • 12.1.1.4.2 Germany: Epilepsy Market Breakdown, by Route of Administration
        • 12.1.1.4.3 Germany: Epilepsy Market Breakdown, by Treatment Type
        • 12.1.1.4.4 Germany: Epilepsy Market Breakdown, by Age Group
        • 12.1.1.4.5 Germany: Epilepsy Market Breakdown, by Distribution Channel
      • 12.1.1.5 France: Epilepsy Market Overview
      • 12.1.1.6 France: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
        • 12.1.1.6.1 France: Epilepsy Market Breakdown, by Type
        • 12.1.1.6.2 France: Epilepsy Market Breakdown, by Route of Administration
        • 12.1.1.6.3 France: Epilepsy Market Breakdown, by Treatment Type
        • 12.1.1.6.4 France: Epilepsy Market Breakdown, by Age Group
        • 12.1.1.6.5 France: Epilepsy Market Breakdown, by Distribution Channel
      • 12.1.1.7 Spain: Epilepsy Market Overview
      • 12.1.1.8 Spain: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
        • 12.1.1.8.1 Spain: Epilepsy Market Breakdown, by Type
        • 12.1.1.8.2 Spain: Epilepsy Market Breakdown, by Route of Administration
        • 12.1.1.8.3 Spain: Epilepsy Market Breakdown, by Treatment Type
        • 12.1.1.8.4 Spain: Epilepsy Market Breakdown, by Age Group
        • 12.1.1.8.5 Spain: Epilepsy Market Breakdown, by Distribution Channel
      • 12.1.1.9 Italy: Epilepsy Market Overview
      • 12.1.1.10 Italy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
        • 12.1.1.10.1 Italy: Epilepsy Market Breakdown, by Type
        • 12.1.1.10.2 Italy: Epilepsy Market Breakdown, by Route of Administration
        • 12.1.1.10.3 Italy: Epilepsy Market Breakdown, by Treatment Type
        • 12.1.1.10.4 Italy: Epilepsy Market Breakdown, by Age Group
        • 12.1.1.10.5 Italy: Epilepsy Market Breakdown, by Distribution Channel
      • 12.1.1.11 Rest of Europe: Epilepsy Market Overview
      • 12.1.1.12 Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
        • 12.1.1.12.1 Rest of Europe: Epilepsy Market Breakdown, by Type
        • 12.1.1.12.2 Rest of Europe: Epilepsy Market Breakdown, by Route of Administration
        • 12.1.1.12.3 Rest of Europe: Epilepsy Market Breakdown, by Treatment Type
        • 12.1.1.12.4 Rest of Europe: Epilepsy Market Breakdown, by Age Group
        • 12.1.1.12.5 Rest of Europe: Epilepsy Market Breakdown, by Distribution Channel

13. Industry Landscape

  • 13.1 Overview
  • 13.2 Growth Strategies in Epilepsy Market
  • 13.3 Organic Growth Strategies
    • 13.3.1 Overview
  • 13.4 Inorganic Growth Strategies
    • 13.4.1 Overview

14. Company Profiles

  • 14.1 Abbott Laboratories
    • 14.1.1 Key Facts
    • 14.1.2 Business Description
    • 14.1.3 Products and Services
    • 14.1.4 Financial Overview
    • 14.1.5 SWOT Analysis
    • 14.1.6 Key Developments
  • 14.2 Pfizer Inc
    • 14.2.1 Key Facts
    • 14.2.2 Business Description
    • 14.2.3 Products and Services
    • 14.2.4 Financial Overview
    • 14.2.5 SWOT Analysis
    • 14.2.6 Key Developments
  • 14.3 Eisai Co Ltd
    • 14.3.1 Key Facts
    • 14.3.2 Business Description
    • 14.3.3 Products and Services
    • 14.3.4 Financial Overview
    • 14.3.5 SWOT Analysis
    • 14.3.6 Key Developments
  • 14.4 UCB SA
    • 14.4.1 Key Facts
    • 14.4.2 Business Description
    • 14.4.3 Products and Services
    • 14.4.4 Financial Overview
    • 14.4.5 SWOT Analysis
    • 14.4.6 Key Developments
  • 14.5 CombiGene AB
    • 14.5.1 Key Facts
    • 14.5.2 Business Description
    • 14.5.3 Products and Services
    • 14.5.4 Financial Overview
    • 14.5.5 SWOT Analysis
    • 14.5.6 Key Developments
  • 14.6 LivaNova Plc
    • 14.6.1 Key Facts
    • 14.6.2 Business Description
    • 14.6.3 Products and Services
    • 14.6.4 Financial Overview
    • 14.6.5 SWOT Analysis
    • 14.6.6 Key Developments
  • 14.7 Novartis AG
    • 14.7.1 Key Facts
    • 14.7.2 Business Description
    • 14.7.3 Products and Services
    • 14.7.4 Financial Overview
    • 14.7.5 SWOT Analysis
    • 14.7.6 Key Developments
  • 14.8 Medtronic Plc
    • 14.8.1 Key Facts
    • 14.8.2 Business Description
    • 14.8.3 Products and Services
    • 14.8.4 Financial Overview
    • 14.8.5 SWOT Analysis
    • 14.8.6 Key Developments
  • 14.9 GSK Plc
    • 14.9.1 Key Facts
    • 14.9.2 Business Description
    • 14.9.3 Products and Services
    • 14.9.4 Financial Overview
    • 14.9.5 SWOT Analysis
    • 14.9.6 Key Developments
  • 14.10 H. Lundbeck AS
    • 14.10.1 Key Facts
    • 14.10.2 Business Description
    • 14.10.3 Products and Services
    • 14.10.4 Financial Overview
    • 14.10.5 SWOT Analysis
    • 14.10.6 Key Developments

15. Appendix

  • 15.1 About The Insight Partners

List Of Tables

  • Table 1. Europe Epilepsy Market Segmentation
  • Table 2. Cell Therapy Approach - An Overview
  • Table 3. Gene Therapy Approach - An Overview
  • Table 4. Encapsulated cell bio delivery (ECB) system Cell and Gene Therapy Approach - An Overview
  • Table 5. Preclinically Tested Genetic Therapies for Epilepsy
  • Table 6. Clinical Trials for Epilepsy Gene Therapy: Overview
  • Table 7. Viral Vectors Comparison with respect to Various Parameters
  • Table 8. Subfamilies of Human K+ Channels Involved in Epilepsies
  • Table 9. Enzyme-Inducing Antiepileptic Drugs
  • Table 10. Enzyme-Inducing Antiepileptic Drugs & Drug Targets Types Overview
  • Table 11. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 12. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 13. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
  • Table 14. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
  • Table 15. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 16. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 17. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 18. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
  • Table 19. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
  • Table 20. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 21. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 22. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 23. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
  • Table 24. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
  • Table 25. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 26. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 27. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 28. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
  • Table 29. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
  • Table 30. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 31. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 32. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 33. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
  • Table 34. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
  • Table 35. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 36. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 37. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 38. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
  • Table 39. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
  • Table 40. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 41. Recent Organic Growth Strategies in Epilepsy Market
  • Table 42. Recent Inorganic Growth Strategies in the Epilepsy Market

List Of Figures

  • Figure 1. Europe Epilepsy Market Segmentation, by Country
  • Figure 2. Epilepsy Market - Key Market Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Epilepsy Market Revenue (US$ Million), 2020-2030
  • Figure 5. Epilepsy Market Share (%) - by Type (2022 and 2030)
  • Figure 6. Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 7. Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 10. Epilepsy Market Share (%) - by Route of Administration (2022 and 2030)
  • Figure 11. Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. Epilepsy Market Share (%) - by Treatment Type (2022 and 2030)
  • Figure 15. First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 17. Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. Epilepsy Market Share (%) - by Age Group (2022 and 2030)
  • Figure 19. Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 20. Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 21. Epilepsy Market Share (%) - by Distribution Channel (2022 and 2030)
  • Figure 22. Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 23. Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 24. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 25. Europe: Epilepsy Market, by Key Country - Revenue (2022) (US$ Million)
  • Figure 26. Europe: Epilepsy Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 27. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 28. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 29. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 30. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 31. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 32. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 33. Growth Strategies in Epilepsy Market